Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$0.44 USD
-0.02 (-4.09%)
Updated May 24, 2024 04:00 PM ET
2-Buy of 5 2
F Value F Growth C Momentum F VGM
Brokerage Reports
Dare Bioscience, Inc. [DARE]
Reports for Purchase
Showing records 1 - 20 ( 212 total )
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Programs, Progress, and Financial Updates; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Neutral Rated: Dare to Present at the International Society for the Study of Women?s Sexual Health (ISSWSH) Annual Meeting
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Progress in Sildenafil Cream Phase 3 Pivotal Study Plan; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Lowering to Neutral: Red Flags Abound, Is a reverse Stock Split Next?
Provider: Dawson James Securities, Inc.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Sells of Future XACIATO Royalties (and Warrants) for $12M, $5M at Closing with an Additional $7M Possible
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
3Q Update as Xaciato Finally Launches; Reiterate Buy; PT Down to $6
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: FSAD is Real and Sildenafil Cream Shows Activity - Additional P2B Data from the RESPOND Study
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -Healthcare Coverage Update
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Dare Bioscience announces first shipment of XACIATO
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Our Top Nuggets from HC Wainwright Global Investment Conference
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Raises $7M for 10M shares ( 10M Warrants) at $0.70
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Dare Has Two Phase 3 Studies in the Works as We Wait for Xaciato Launch; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
NICHD Grant to Aid Preclinical Studies in Idiopathic Preterm Birth
Provider: Roth Capital Partners, Inc.
Analyst: RAJA K
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
Another Look at Sildenafil Cream Tells Us It Shouldn''t Be Overlooked
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: CytoSorbents Completes Enrollment of the STAR-T Pivotal Trial
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Dare Provides an Update on the Launch of XACIATO
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J
Company: Dare Bioscience, Inc.
Industry: Medical - Biomedical and Genetics
BUY: Steady Progress as We Move in the Second Half
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: KOLBERT J